Remplir™ Gains Australian Reimbursement

1 November 2022
Posted in Media
1 November 2022 Orthocell

Orthocell’s breakthrough product for peripheral nerve repair, Remplir™, has now gained Australian reimbursement –  inclusion on the Australian Prostheses List – which is an important step in providing efficient and affordable access to this device.

Remplir™ was recently cleared for use in Australia by the TGA and an exclusive AU/NZ distributor appointed, Device Technologies.

Australia represents a significant addressable market, with 11,780 surgical repairs of peripheral nerves completed in the 2019/20 financial year, and Orthocell is now ideally positioned to expand its reach into the US, the largest global healthcare market in the world.

Click here to read today’s ASX release.